reports
UCB SA: 2 directors
Two Directors at UCB SA sold/bought 1,385 shares at 128.760USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Louis Boujard
- CFA
- Philippe Ourpatian
BMW BAYERISCHE MOTOREN WERKE AG
UBSN UBS GROUP AG
ALO ALSTOM SA
ELE ENDESA S.A.
VER VERBUND AG CLASS A
BA. BAE SYSTEMS PLC
BC8 BECHTLE AG
FDR FLUIDRA S.A.
EDW EDP RENOVAVEIS SA
AMS AMADEUS IT GROUP SA CLASS A
PRY PRYSMIAN S.P.A.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ARGX ARGEN-X SE
KBX KNORR-BREMSE AG
NEXI NEXI S.P.A.
ENR SIEMENS ENERGY AG
ARM ARM HOLDINGS PLC
- Louis Boujard
- CFA
- Philippe Ourpatian
BMW BAYERISCHE MOTOREN WERKE AG
UBSN UBS GROUP AG
ALO ALSTOM SA
ELE ENDESA S.A.
VER VERBUND AG CLASS A
BA. BAE SYSTEMS PLC
BC8 BECHTLE AG
FDR FLUIDRA S.A.
EDW EDP RENOVAVEIS SA
AMS AMADEUS IT GROUP SA CLASS A
PRY PRYSMIAN S.P.A.
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ARGX ARGEN-X SE
KBX KNORR-BREMSE AG
NEXI NEXI S.P.A.
ENR SIEMENS ENERGY AG
ARM ARM HOLDINGS PLC
- Damien Choplain
- Martial Descoutures
Argenx : Product ramp-up continues
>Q1 in line on sales, below on EBIT - Q1 sales grew by 83% y-o-y and 6% q-o-q to $ 398m (US $ 347m, Japan $ 18m and EMEA $ 31m), reflecting the strong medical need in myasthenia gravis, the quality of products (i.e. Vyvgart and Vyvgart Hytrulo), as well as the excellent execution of the commercial rollout. The product should remain on this growth trajectory to achieve peak sales estimated at $ 11bn (vs the consensus at $ 11bn) in 2035, driven by the recent launch of ...
- Wedbush Research
TXRH TEXAS ROADHOUSE INC.
RNG RINGCENTRAL INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
IMAX IMAX CORPORATION
GLPI GAMING AND LEISURE PROPERTIES INC.
DIN DINE BRANDS GLOBAL INC.
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
CAKE CHEESECAKE FACTORY INCORPORATED
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
BJRI BJ'S RESTAURANTS INC.
DRI DARDEN RESTAURANTS INC.
OKTA OKTA INC. CLASS A
RCUS ARCUS BIOSCIENCES
ZS ZSCALER INC.
UBER UBER TECHNOLOGIES INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
IGMS IGM BIOSCIENCES
DDOG DATADOG INC CLASS A
RVMD REVOLUTION MEDICINES
ABNB AIRBNB INC. CLASS A
PHVS PHARVARIS NV
RMBL RUMBLEON INC
APP APPLOVIN CORP
BIRD ALLBIRDS INC
JANX JANUX THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
CART MAPLEBEAR INC.
- Hilde Van Boxstael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx FIRST LOOK: 1Q24 results on track, all eyes set on CIDP
This morning argenx reported its 1Q24 update, highlighting $ 398m sales and its pipeline progress. Mgmt is fully focused on expanding its commercial footprint into CIDP (PDUFA: June 21). Meanwhile, AAV was scrapped from the pipeline and systemic sclerosis (SSC) added. We maintain our € 435 TP and Buy rating.
- Damien Choplain
- Martial Descoutures
Argenx : La montée en puissance des produits se poursuit
>T1 en ligne sur les ventes, en dessous sur l’EBIT - Les ventes T1 progressent de 83% y-o-y et de 6% q-o-q pour atteindre 398 M$ (US 347 M$, Japon 18 M$ et EMEA 31 M$), reflétant le fort besoin médical dans la Myasthénie Gravis, la qualité des produits (i.e. Vyvgart et Vyvgart Hytrulo), ainsi que l’excellente exécution du déploiement commercial. Le produit devrait rester sur cette trajectoire de croissance pour atteindre un peak sales estimé à 11 Md$ (vs css 11 Md$) ...
argenx Reports First Quarter 2024 Financial Results and Provides Busin...
argenx Reports First Quarter 2024 Financial Results and Provides Business Update $398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second quarter 2024 Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 9, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its fi...
- Laura Chico
- David Seynnaeve
- PhD
argenx - Q1 beat on CSS
• Argenx published its Q1 update in which VYVGARD revenues slightly beat CSS by 2%• Two key news items: 1/ filing for the pre-filled syringe syringe for gMG and CIDP to be submitted in Q2 24 and 2/ decision to discontinue the planned development of efgartigimod in ANCA-associated vasculitis (AAV) following risk assessment of all ongoing studies based on learnings from ADDRESS and ADVANCE SC studies. CIDP PDUFA target action date of June 21 reiterated• Cash position stood at USD 3.1bn end of Marc...
Pharvaris Reports First Quarter 2024 Financial Results and Provides Bu...
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacksExecuting from a strong financial position with cash and cash equivalents of €368 million as of March 31, 2024 ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists t...
argenx announces results of Annual General Meeting of Shareholders
argenx announces results of Annual General Meeting of Shareholders May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held today. All items on the agenda received a majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). As part of the approved resolutions: The Company's annual report and annual accounts for the financial year ending...
GenSight Biologics annonce la mise à disposition d'un prospectus à l'o...
PARIS--(BUSINESS WIRE)-- Regulatory News: CE COMMUNIQUE DE PRESSE N'EST PAS DIFFUSE ET DES COPIES NE PEUVENT PAS ETRE DISTRIBUEES OU ENVOYEES, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS, AU CANADA, EN AFRIQUE DU SUD, AU JAPON OU EN AUSTRALIE. GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, éligible PEA-PME) (la "Société"), une Société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et les troubles du système nerveux central, a annoncé aujourd'hui la mise à disposition d...
GenSight Biologics: Assemblée Générale Mixte du 29 mai 2024
PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce la tenue de son Assemblée Générale Mixte le 29 mai 2024 à 9h00 au siège social de la Société, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. L’Assemblée Générale sera également retransmise en direct pour les actionnaires sur le site Internet de la Société ...
GenSight Biologics: Annual General Meeting on May 29, 2024
PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 29, 2024, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting will also be webcast live for shareholders on the Company’s website (). The notice containing the agenda and draft re...
Ipsen S.A. - Formalities for making available and consulting preparato...
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting Information relating to the holding of the Combined Shareholders’ Meeting of 28 May 2024 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting BOULOGNE-BILLANCOURT, FRANCE, 7 May 2024 - The Shareholders of the Company are invited to participate in the Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Tuesday 28 May 2024 at 3:00 p.m. (Paris time) at the Salons de l'Hôtel des Arts et M...
IPSEN SA. - Modalités de mise à disposition et de consultation des doc...
IPSEN SA. - Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Mixte du 28 mai 2024 Informations concernant la tenue de l’Assemblée Générale Mixte du 28 mai 2024 d’Ipsen S.A. Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée BOULOGNE-BILLANCOURT, FRANCE, 7 mai 2024 - Les actionnaires de la Société sont invités à participer à l’Assemblée Générale Mixte d’Ipsen (Euronext : IPN ; ADR : IPSEY), qui se tiendra le mardi 28 mai 2024 à 15h00 (heure de Paris) aux Salons d...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Resul...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025Reported significant improvements observed across all key outcomes with sonelokimab over 24 weeks in the ARGO Phase 2 trial in active psoriatic arthrit...
- Olfa Taamallah
- Yan Derocles
VLS VALNEVA SE
ELG ELMOS SEMICONDUCTOR SE
NOEJ NORMA GROUP SE
ELIS ELIS SA
SHA SCHAEFFLER AG
KRN KRONES AG
PSPN PSP SWISS PROPERTY AG
SIGHT GENSIGHT BIOLOGICS SA
BEZ BERENTZEN GRUPPE
ASS APPLUS SERVICES S.A.
COFA COFACE SA
JUN3 JUNGHEINRICH AG PREF
IDR INDRA SISTEMAS S.A. CLASS A
TMV TEAMVIEWER AG
HAG HENSOLDT AG
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.